This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Padula WV, Parasrampuria S, Socal MP, et al. Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US. PharmacoEconomics. 2020;38:1115–21. https://doi.org/10.1007/s40273-020-00934-2.
Lichenberg FR, Waldfogel J. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. NBER Working Paper No. 9750, June 2003. 2003. https://www.nber.org/papers/w9750. Accessed 29 Oct 2020.
Reaves ND. A model of effective health policy. J Health Soc Policy. 2003;17(4):61–71. https://doi.org/10.1300/J045v17n04_04.
Manning R, Stomberg C, Scher B, Twigg K, Huson A. Similar products at different prices: can biopharmaceutical companies segment markets? Int J Econ Bus. 2015;22(2):231–43. https://doi.org/10.1080/13571516.2015.1045739.
Conflict of Interest
Richard Manning is a consultant to several clients with interests in healthcare, including law firms, government agencies, branded and generic/biosimilar biopharmaceutical manufacturers, health insurers, and trade organizations.
Consent to Participate
Consent for Publication
Data Availability and Material
About this article
Cite this article
Manning, R. Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”. PharmacoEconomics 38, 1373–1374 (2020). https://doi.org/10.1007/s40273-020-00975-7